Charlie's Holdings, Inc. 10-Q

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of the financial condition and results of operations of Charlie ’ s Holdings, Inc. should be read in conjunction with the financial statements and the notes to those statements appearing elsewhere in this Quarterly Report on Form 10-Q (this “ Report ” ) and without audited financial statements and other information presented in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “ 2025 Annual Report ”) . Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Report, and in our other filings with the Securities and Exchange Commission ( “ SEC ” ), including particularly matters set forth under Part I, Item 1A (Risk Factors) of the 2025 Annual Report. Furthermore, such forward-looking statements speak only as of the date of this Report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. As used in this Report, unless otherwise stated or the context otherwise requires, references to the “ Company ” , “ we ” , “ us ” , “ our ” , or similar references mean Charlie ’ s Holdings, Inc., its subsidiaries and consolidated variable interest entity on a consolidated basis. Overview Charlie's is a leader in the premium vapor products industry. Long known for its pioneering history and award-winning products, the Company’s mission is to provide adult smokers with better alternatives to combustible cigarettes. To this end, Charlie’s has developed a family of proprietary e-liquids as well as an array of compact, easy-to-use disposable vaping devices. The Company’s products are sold around the world to select distributors, specialty retailers, and third-party online resellers. The Company’s objective is to become a sales leader in two broad product categories: (i) non-combustible nicotine-related products and (ii) alternative alkaloid (non-nicotine) vapor products. In pursuit of these targets, Charlie’s primary strategic focus is on the development of intellectual property related to product access and compliance. The Company is investing in the development of advanced age-gating and access-control technologies designed to prevent youth access while maintaining availability for adult smokers who seek alternatives to combustible cigarettes. The Company believes that effective age-verification mechanisms are a critical component in supporting Charlie’s Premarket Tobacco Applications (“ PMTAs ”) for both flavored and “plain” tobacco nicotine vapor products. In December 2025, the Company signed a definitive licensing agreement with IKE Tech LLC (“ IKE ”) to commercialize the first-ever AI-powered blockchain-based age-gating system for vapor products in the United States. The Company believes that demonstrating robust age-gating capabilities through this technology could support a showing to the FDA that its flavored ENDS products are "appropriate for the protection of public health," consistent with the PMTA review standard. A successful regulatory outcome could prove transformational for the Company's flavored product portfolio and for the vapor products industry more broadly. Strategic Priorities In today’s economic landscape, particularly within the vapor products industry, seeking and securing competitive advantage is paramount. Unlike many competitors in our industry, Charlie’s has focused on achieving full compliance with FDA regulations – while also establishing a regulatory “hedge” through the development of alternative “zero-nicotine” product lines that are not currently subject to FDA review. Simultaneous to undertaking these initiatives, in 2025 management took aggressive steps to (i) monetize sixteen of the Company’s PMTA products, (ii) launch the SBX product line, (iii) establish a U.S. manufacturing facility, and (iv) achieve profitability. Charlie’s success, in all these endeavors, set the stage for continued growth, potential FDA marketing orders, and a potential uplist to a national securities exchange. Accordingly, here are the primary strategic initiatives on which we intend to focus in 2026: ● Grow sales and retail distribution through chain convenience stores in select markets across the US. ● Utilize the IKE age-gating license to deploy age-gated SBX disposables, accumulate real-world compliance data, and amend the Company's PACHA PMTAs to incorporate age-gating — positioning Charlie's to demonstrate to the FDA that its flavored vapor products are "appropriate for the protection of public health." ● Introduce cutting edge 75K-Puff disposable devices for both the SBX and the Pachamama product lines ● Form new strategic partnership(s) to monetize the Company's PMTA-submitted PACHA synthetic nicotine products. ● Grow international sales to mitigate US regulatory risks. 18 ● Uplist to a National Securities Exchange Collectively, all these initiatives represent Charlie's commitment to adult smokers. Through innovation and a hyper-focus on quality, our Company strives to provide our customers with an exceptionally satisfying vaping experience. In order to put the value of some of these initiatives into context, here is a more detailed overview of our business plans and strategy: I. Grow Charlie’s sales and retail distribution Grow SBX sales and distribution through chain convenience stores in select markets across the United States Our market research indicates that adult consumers overwhelmingly prefer "flavored" vapor products over plain tobacco products and are highly receptive to nicotine substitute products that offer the same vaping experience as that provided by conventional nicotine vapor products. SBX Disposables feature Charlie's award-winning flavors (preferred over plain tobacco vapor by more than 80% of adult consumers). SBX nicotine analogue-based vape liquids are not made from or derived from tobacco, nor do they contain nicotine from any source. Accordingly, the Company's proprietary nicotine substitute alkaloid (patented in the United States and in China by the Company's chemical supplier) does not meet the definition of "nicotine" and therefore SBX products are not subject to FDA PMTA requirements and are LEGAL across most of the United States. SBX Beats Juul … 15:1 In a Company-sponsored focus group survey of adult consumers who vape, Charlie's SBX flavored Disposables were overwhelmingly preferred over Juul tobacco-flavored vapes. Of 306 survey participants, 287 preferred SBX over Juul. Despite the fact that adult consumers overwhelmingly prefer flavored ENDS products, the FDA has granted marketing authorization to only two (2) non-tobacco, non-menthol “fruit flavored” ENDS products (blueberry and mango flavored pods made by Glas Vapor). Due to a patent dispute, Glas’ newly authorized “fruit flavored” products are unlikely to go on the market any time soon. Juul Labs filed a patent infringement lawsuit against Glas, Inc. in the U.S. District Court for the Central District of California and also launched an investigation with the U.S. International Trade Commission (ITC). Juul alleges that Glas's vapor products and e-cigarette technologies violate their proprietary hardware and design patents. Under these circumstances, the overwhelming majority of flavored ENDS products on the market today remain unauthorized under the current PMTA framework. With enforcement remaining limited, illicit flavored ENDS products are widely available across the United States, and the FDA Center for Tobacco Products estimates that more than half of the U.S. e-cigarette market consists of illicit products. In response, certain states have enacted legislation restricting or banning flavored nicotine products. In those states, compliant products such as SBX benefit from a structural competitive advantage, and the Company is focusing its SBX sales initiatives accordingly. We believe the number of states where SBX holds this regulatory advantage will continue to grow. Grow Pachamama/PACHA sales and distribution in select markets across the United States Distinguished by award-winning flavors and by Charlie’s commitment to regulatory compliance, PACHA and Pachamama are well-known brands that are positioned to grow significantly in 2026. The Company plans to leverage the brands’ emerging and distinct competitive advantages: ● Pachamama is the ONLY vapor products brand that has been on the market for more than a decade and is now fully compliant with Texas domestic manufacturing requirements; ● Pachamama will be one of the select brands that is fully compliant with Indiana’s “foreign adversary prohibited” manufacturing legislation (going into effective July 1, 2026); ● PACHA Virginia Tobacco 12mL, 8mL, and 4mL Disposables were all approved in March 2026 for inclusion on the State of California’s Unflavored Tobacco List (“ UTL ”). This designation means that PACHA Virginia Tobacco Disposables are legal to sell in all smoke shops, gas stations, and c-stores throughout the State of California. ● PACHA flavored 12mL, 8mL, and 4mL Disposables, as well as the Company’s PACHA e-liquids, have all been approved for inclusion on the Nebraska State Directory. ● PACHA flavored 4mL and 8mL Disposables are among the select few flavored disposables that have been approved by the state of Louisiana With growing number of states instituting state registries each year, we believe that Pachamama, and PACHA and (non-nicotine) SBX will expect to see continued (and growing) success in the marketplace and that Charlie’s competitive advantages will expand significantly. II. Utilize the IKE Age-Gating technology to secure unprecedented Regulatory Competitive Advantages Currently, there is a need for age-gated product technologies that can satisfy or accommodate concerns the FDA has related to under-age youth access. We believe age-gating is both a responsible business practice as well as a potential future competitive advantage for Charlie's. 19 In January 2026 we reported that the Company signed a definitive licensing agreement with IKE Tech LLC (“IKE”) to commercialize the first-ever AI-powered blockchain-based age-gating system for vape products in the United States. Utilizing the patented technology that IKE validated in a multi-center Human Factors Validation Study, Charlie’s plans to launch an age-gated product in 200-300 compliance-minded retail stores in Q3 2026. The test-market initiative will incorporate the age-gating system in a special line of the Company’s flavored ENDS disposables; simultaneously, Charlie’s intends to amend certain of its existing Premarket Tobacco Applications (PMTAs) with the FDA for PACHA brand ENDS with the IKE system. PACHA brand Electronic Nicotine Delivery Systems (ENDS) with FDA PMTA’s Charlie’s intends to collect market data from sales of its age-gated disposables which it will use to amend the Company’s existing PMTAs with the FDA to include age-gating provisions for certain of the Charlie’s PACHA brand nicotine disposables. There is a significant unmet need for technologies that address the FDA's concerns regarding youth access to vapor products, representing a substantial market opportunity for flavored vapes that are inoperable for underage individuals. By deploying age-gated disposables under the IKE license and accumulating real-world compliance data — while simultaneously amending the Company's PACHA PMTAs to incorporate age-gating technology — the Company believes it can demonstrate to the FDA that its flavored vapor products are "appropriate for the protection of public health." The Company believes a successful regulatory outcome would be transformational for Charlie's flavored product portfolio and could establish a meaningful precedent for the broader vapor products industry. III. Introduce cutting-edge 75K Puff disposable devices for both the SBX and the Pachamama product lines Specifically designed with consumer needs and preferences in mind, Charlie’s new generation of 75K Disposables feature an impressive Dual Mesh Coil and provide significantly more vape… and surprisingly better taste… than market-leading disposables. With a large tank capacity, SBX and Pachamama 75K Disposables offer 75,000 uniquely satisfying puffs and feature a transparent shell for accurate liquid measurement, easy-to-use button control, and low-key LED indicators. Both brands feature three power modes, allowing users to select "ECO MODE," "BOOST MODE," or "X MODE"… while simultaneously providing adjustable airflow settings that range from "tight and very enjoyable," to "the standard experience," to "no restrictions." SBX and Pachamama 75K Disposables each offer fourteen of Charlie's most popular award-winning flavors. Initial orders will ship in Q2 2026. IV. Form new strategic partnership(s) to monetize the Company’s PMTA-submitted PACHA synthetic nicotine products. In 2025, in three separate transactions, Charlie's sold sixteen of the Company's PACHA synthetic nicotine PMTA products and related assets for $7.5MM cash plus a contingent one-time payment of up to $4.2 million. In the last of the three transactions, the buyer purchased a single Charlie’s PMTA product for $1MM. Based on these sales, taking into account the fact that Charlie’s continues to own 678 PMTA products, and considering the interest other companies have expressed in Charlie's portfolio, the Company believes Charlie's remaining PMTA products, as a stand-alone asset, could have a significant monetary value . To maximize the value of this portfolio, the Company intends to (i) continue to amend and strengthen Charlie’s PMTAs with new scientific data, (ii) add age-gating functionality to certain of our PMTAs, and (iii) explore new strategic partnerships with industry competitors, big and small, that value regulatory compliance in the vapor products marketplace. V. Grow International Sales to mitigate US regulatory risks In order to further mitigate FDA regulatory risk in the domestic market and to capture what management continues to believe is a significant commercial opportunity, we have dedicated additional resources to efforts focused on growing our market share internationally. Presently, approximately 8% of our vapor product sales come from the international market. We are well-positioned to increase sales in countries where we already have presence and to capture new business in several additional overseas markets. VI. Uplist to a National Securities Exchange We believe that upon a successful uplisting to a national securities exchange, we will significantly improve our capital markets appeal to a broader range of investors, increase our liquidity, and ultimately, achieve a higher market cap for the Company. 20 Risks and Uncertainties The Company operates in an environment that is subject to rapid changes and developments in laws and regulations that could have a significant impact on the Company’s ability to sell its products. Beginning in September 2019 , certain states temporarily banned the sale of flavored e-cigarettes, and several states and municipalities are considering implementing similar restrictions. Federal, state, and local governmental bodies across the United States have indicated that flavored e-cigarette liquid, vaporization products and certain other consumption accessories may become subject to new laws and regulations at the federal, state, and local levels. In addition, in September 2022, the FDA announced a plan to reduce nicotine levels in cigarettes to minimally or non-addictive levels. The application of any new laws or regulations that may be adopted in the future, at a federal, state, or local level, directly or indirectly implicating nicotine, flavored e-cigarette liquid, and other electronic nicotine delivery system (“ ENDS ”) products, could significantly limit the Company’s ability to sell such products, result in additional compliance expenses, and/or require the Company to change its labeling and/or methods of distribution. Any ban of the sale of flavored e-cigarettes directly limits the markets in which the Company may sell its products. In the event the prevalence of such bans and/or changes in laws and regulations increase across the United States, or internationally, the Company’s business, results of operations, and financial condition could be adversely impacted. In addition, the Company is presently seeking to obtain marketing authorization for certain of its tobacco-derived nicotine e-liquid products. The Company’s applications were submitted in September 2020 on a timely basis, which if approved, will allow the Company to continue to sell its approved products in the United States. Beginning in August 2021, the FDA began issuing Marketing Denial Orders (“ MDO ”) for ENDS products that lack evidence to demonstrate that permitting the marketing of such products would be appropriate for the protection of the public health. On April 1, 2026, the Company received an MDO from the FDA with respect to certain SKUs of our timely-submitted 2020 PMTAs. On May 1, 2026, the Company filed a Petition for Review challenging the MDO with the U.S. Court of Appeals for the Fifth Circuit. On May 11, 2026 the Company moved to stay the MDO pending judicial review. The Company anticipates the Court ruling on our opposed stay motion on or about the beginning of June 2026. Though only a very small percentage of our current sales are related to these affected PMTA e-liquid products, we plan to vigorously defend our PMTA products on the merits while also continuing to amend our applications with the latest science. Notably, the Company has not received an MDO for its 2020 “tobacco-flavor” PMTA submission; however, there is no assurance that regulatory approval to sell our products will be granted or that we would be able to raise additional financing if required, which could have a significant impact on our sales. On March 15, 2022, a new rider to the Federal Food, Drug and Cosmetic Act was passed granting the FDA authority over synthetic nicotine. These regulations make the Company’s synthetic nicotine products subject to the same FDA rules as tobacco-derived nicotine products. As such, the Company was required to file a PMTA for its existing synthetic nicotine products marketed under the Pacha brands by May 14, 2022 or be subject to FDA enforcement. The Company filed new PMTAs for its synthetic Pacha products on May 13, 2022, prior to the May 14, 2022 deadline. On November 3, 2022, FDA accepted for scientific review certain of our PMTAs for synthetic nicotine products and, on November 4, 2022, FDA refused to accept certain other PMTAs for these products, rendering the latter products subject to FDA enforcement. The Company submitted an administrative appeal with FDA regarding its refusal to accept certain of the PMTAs. The administrative appeal was granted on October 30, 2023 and the products were accepted to move forward in the PMTA review process. On October 28, 2025, the Company received an MDO from the FDA with respect to certain of our timely-submitted PMTAs. On November 5, 2025, the Company filed a motion for a temporary administrative stay with the United States Court of Appeals for the Fifth Circuit. On November 10, 2025, the Court granted the Company's opposed motion for a temporary administrative stay pending resolution of our forthcoming stay motion. On December 24, 2025, a Fifth Circuit panel granted our motion to stay the MDOs pending judicial review. As a result of the stay, the affected PMTAs revert to pending status and continue to be treated as timely filed (May 2022) while the case is litigated on the merits. Accordingly, the subject products remain eligible, where permitted by state law, for listing on state vapor products directories (e.g. Louisiana) that allow the sale of products associated with timely submitted synthetic nicotine PMTAs that are pending FDA's review, subject to satisfaction of all other applicable state requirements. Though only a very small percentage of our current sales are related to our affected PMTA Products, we plan to vigorously defend our PMTAs on the merits while also continuing to amend our applications with the latest science. The Company recently launched new alternative alkaloid Metatine-based disposable vape products, under the “SBX™” brand, that the Company expects will (i) replace a significant portion of its legacy products and (ii) become the single largest, most important commercial opportunity in Charlie’s history. The Company and its attorneys believe Metatine-based products are not subject to FDA review. Based on the information provided by the Company’s contracted chemical suppliers and its consultants, the proprietary Metatine™ (patented in the United States and in China by the Company’s chemical supplier) in the Company’s alternative alkaloid products does not meet the definition of nicotine set forth in 21 U.S.C. § 387(12) and therefore its products containing Metatine, as their active ingredient, are not subject to regulation as “tobacco products” under 21 U.S.C. § 321(rr). Further, according to information provided by the Company’s chemists, the other ingredients in the Company’s alternative alkaloids vape liquid are not made or derived from tobacco, nor do they contain nicotine from any source. The documentary support for these facts, including a Certificate of Analysis (COA) for the Metatine used in the Company’s alternative alkaloid products, corroborates these conclusions. However, should Congress bestow regulatory control over Metatine to the FDA, or should the FDA deem Metatine disposable vape devices “tobacco products” despite the facts that Metatine is not a salt or complex of nicotine, and is not itself derived from nicotine or tobacco, Metatine-based products might then be subject to the FDA tobacco requirements, including, but not limited to, the requirement that all newly deemed tobacco products obtain premarket authorization before entering the U.S. market. If this were to happen, the FDA could bring an enforcement action against our Metatine products for lack of premarket authorization. More generally, FDA’s regulatory initiatives and enforcement authority regarding our products are unpredictable and continue to evolve and we cannot predict whether FDA’s priorities and/or potential jurisdiction over our products will prompt the Agency to attempt to require us to remove our products from the market and to cease selling them. 21 Recent Developments Private Placement – February 13, 2026 On February 13, 2026, the Company completed a private placement of 3,550,000 shares of its common stock at a purchase price of $0.20 per share, resulting in aggregate consideration of $710,000. Of the total consideration, $510,000 was received in cash and $200,000 was satisfied through the forgiveness of certain outstanding indebtedness owed by the Company (see Note 9). The issuance of shares increased the Company’s liquidity and reduced a portion of its outstanding debt obligations. Charlie’s management and directors purchased 1,350,000 shares of the 3,550,000 total shares that were sold, as follows: Name Title Shares Purchased Michael King Independent Director 500,000 Edward Carmines Independent Director 250,000 Ryan Stump Director and Chief Operating Officer 250,000 Henry Sicignano III President 250,000 Matthew Montesano Chief Financial Officer 100,000 U.S. Food and Drug Administration Expands Market Access – May 5, 2026 On May 5, 2026, The U.S. Food and Drug Administration (“ FDA ”) authorized the marketing of four Glas Inc.’s age-gated electronic nicotine delivery systems (“ ENDS ”) through the premarket tobacco product application (“ PMTA ”) pathway. Each product is an e-liquid pod containing 50mg/ml (or 5%) of tobacco-derived nicotine. The authorized pods include Classic Menthol and Fresh Menthol, as well as two “fruit flavors,” Gold, and Sapphire. This action marks the FDA’s first authorization of non-tobacco, non-menthol “fruit-flavored” ENDS products. Industry officials view these developments – combined with the May 12, 2026 resignation of FDA Commissioner Marty Makary – as a sign that the FDA’s long-standing resistance to broader flavored vape approvals may be starting to soften. Private Placement – May 20, 2026 On May 20, 2026, the Company completed a private placement of 8,750,000 shares of its common stock at a purchase price of $0.20 per share, resulting in aggregate consideration of $1,750,000. Of the total consideration, $750,000 was received in cash and $1,000,000 was satisfied through the forgiveness of certain outstanding indebtedness owed by the Company (see Note XX). The issuance of shares increased the Company’s liquidity and reduced a portion of its outstanding debt obligations. 22 Results of Operations for the Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025 A review of the three-month period ended March 31, 2026, follows: For the three months ended March 31, Change 2026 2025 Amount Percentage ($ in thousands) Product revenue, net $ 4,804 $ 1,578 $ 3,226 204.4 % Cost of goods sold - product revenue 3,624 1,192 2,432 204.0 % Gross profit 1,180 386 794 205.7 % Operating costs and expenses: General and administrative 1,738 1,086 652 60.0 % Sales and marketing 383 173 210 121.4 % Research and development 34 6 28 466.7 % Total operating costs and expenses 2,155 1,265 890 70.4 % Loss from operations (975 ) (879 ) Other income (expense): Interest expense (75 ) (241 ) 166 -68.9 % Debt extinguishment loss - (149 ) 149 -100.0 % Total other loss (75 ) (390 ) 315 -80.8 % Loss before provision for income taxes (1,050 ) (1,269 ) 219 -17.3 % Loss from continuing operations after income taxes (1,050 ) (1,269 ) Discontinued operations: Income from discontinued operations, net of tax - 52 (52 ) -100.0 % Net loss $ (1,050 ) $ (1,217 ) $ 167 -13.7 % Revenue Revenue for the three months ended March 31, 2026, increased by approximately $3,226,000 or 204.4%, to approximately $4,804,000, as compared to approximately $1,578,000 for same period in 2025, which is all due to the increase in our nicotine-based product and nicotine alternative products sales. Sales of SBX, a non-nicotine, disposable vapor product which is not subject to FDA review, experienced a significant increase in 2026. Cost of Revenue Cost of revenue, which consists of direct costs of materials, direct labor, third party subcontractor services, and other overhead costs increased by approximately $2,432,000 or 204.0%, to approximately $3,624,000, or 75.4% of revenue, for the three months ended March 31, 2026, as compared to approximately $1,192,000, or 75.5% of revenue, for the same period in 2025. This cost increased compared to last year due primarily to an increase in the volume of products sold during the period. General and Administrative Expenses For the three months ended March 31, 2026, total general and administrative expenses increased $652,000 to $1,738,000 as compared to approximately $1,086,000 for the same period in 2025. The increase was primarily comprised of an increase of approximately $284,000 of non-commission wages and benefits, $90,000 of professional fees, as well as $278,000 in other general and administrative expenses. The increase in non-commission wages and benefits of $284,000 reflects headcount additions in operations and manufacturing to support the Company's revenue growth during the period. The $90,000 increase in professional fees was primarily driven by higher legal and board-related costs incurred during the period. The $278,000 increase in other general and administrative expenses was driven by higher occupancy costs, bad debt expense, and merchant processing fees — the latter of which increases commensurately with sales volume. 23 Sales and Marketing Expense For the three months ended March 31, 2026, total sales and marketing expense was approximately $383,000 as compared to approximately $173,000 for the same period in 2025. The increase was primarily due to increased sales commissions paid as well as a significant increase in tradeshow and customer event related costs. The Company continues to evaluate its spending on advertising, promotional and tradeshow related expenses as it aims to increase sales of its new SBX Disposable vapor products. Research and Development Expense For the three months ended March 31, 2026, total research and development expense was approximately $34,000 as compared to $6,000 for the same period in 2025. The $28,000 increase reflects ongoing product development and testing activity in support of the Company's active PMTA portfolio, consistent with management's strategy of advancing regulatory approvals for its nicotine product lines. Income (Loss) from Operations We incurred a loss from operations of approximately $975,000 for the three months ended March 31, 2026, compared to a loss of approximately $879,000 for the same period in 2025, due primarily to higher general and administrative expenses. Net income (loss) is determined by adjusting loss from operations by the following items: ● Interest Expense. For the three months ended March 31, 2026, and 2025, we recorded interest expense related to notes payable of approximately $75,000 and $241,000, respectively. The decrease was primarily due to the payoff of a significant amount of outstanding notes payable. ● Debt Extinguishment Loss. For the three months ended March 31, 2025, we recorded approximately $149,000 debt extinguishment related to various debt amendments. Net Loss For the three months ended March 31, 2026 and 2025, we incurred net loss of $1,050,000 and $1,269,000, respectively. Effects of Inflation Inflation has not had a material impact on our business. Liquidity and Capital Resources As of March 31, 2026, we had working capital of approximately $4,843,000, which consisted of current assets of approximately $14,117,000 and current liabilities of approximately $9,274,000, as compared to working capital of approximately $3,137,000 at December 31, 2025. The current liabilities include approximately $8,751,000 of accounts payable and accrued expenses and approximately $260,000 of deferred revenue associated with product shipped but not yet received by customers. 24 Our cash and cash equivalents balance at March 31, 2026 was approximately $640,000. As of March 31, 2026, we have the following notes outstanding: ● Amended August 2025 Notes. As of March 31, 2026, $2,000,000 notes payable plus accrued interest held by Michael King remained outstanding. For the three months ended March 31, 2026, net cash used in continuing operating activities was approximately $1,105,000, resulting from a net loss from continuing operations of $1,050,000 and a change in operating assets and liabilities of $130,000, and offset by a net non-cash activity of $75,000. For the three months ended March 31, 2025, net cash used in continuing operating activities was approximately $691,000, resulting from a net loss from continuing operations of $1,269,000 and offset by a change in operating assets and liabilities of $244,000 and net non-cash activity of $334,000. For the three months ended March 31, 2026, we generated approximately $425,000 in cash from financing activities related to the issuance of common shares of $510,000 and the repayment of $85,000 in notes payable to a related party. For the three months ended March 31, 2025, we generated approximately $310,000 in cash from financing activities related to the issuance of notes payable of $546,000, notes payable to a related party of $100,000 and the repayment of $325,000 in notes payable, including $11,000 to a related party. Going Concern Regarding the Legal and Regulatory Environment, Liquidity and Management ’ s Plan of Operation Our condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2026, the Company’s revenue increased, the Company incurred a loss from operations of approximately $975,000, and a net loss from continuing operations of approximately $1,050,000. Net cash used in continuing operating activities was approximately $1,105,000. The Company had a stockholders’ equity of $3,108,000 at March 31, 2026. During the three months ended March 31, 2026, the Company’s working capital was increased to $4,843,000 from $3,137,000 as of December 31, 2025. Management evaluated whether these conditions could raise a substantial doubt about the Company’s ability to continue as a going concern. During the year ended December 31, 2025, the Company entered into and closed an Asset Purchase Agreement (the “Agreement”) and subsequent amendment with one of the world’s largest tobacco companies (the “Buyer”) pursuant to which the Buyer purchased 16 of the Company’s PACHA synthetic products and related assets (the “Assets”) that are covered by a premarket tobacco application (“PMTA”) first submitted by the Company in 2022. The combined purchase price for the Assets was $6.5 million paid at closings in April and May 2025, and an additional $1.0 million paid at closings in August 2025, plus a contingent one-time payment of up to $4.2 million based on product sold by the Buyer during the one year following the first day of commercialization of the Assets. The proceeds from these transactions have significantly improved the Company’s liquidity position, reduced outstanding obligations, and strengthened working capital. In addition, management has implemented and continues to execute on initiatives designed to enhance operating performance and liquidity, including (i) focusing on growth in the Company’s non-combustible, alternative alkaloid (non-nicotine) products, (ii) advancing regulatory approval efforts for the Company’s nicotine product portfolio, and (iii) the continued development of intellectual property related to product access and compliance. The Company is also pursuing additional strategic transactions, including potential PMTA-related asset sales, which may provide incremental liquidity. Based on these factors, management believes the Company is adequately capitalized to support its operations and meet its obligations as they come due for at least the next twelve months. 25 Off-Balance Sheet Arrangements The Company has no off-balance sheet arrangements other than operating lease commitments. Critical Accounting Policies The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expense in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report on the 2025 Annual Report. ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Not applicable.